Inpharma Weekly

, Volume 1074, Issue 1, pp 9–10 | Cite as

High hopes for Cel-Sci’s ‘LEAPS’ vaccine technology

  • Gill Higgins
Newsletter Article


The aim of research at Cel-Sci is to develop vaccines that can improve the fighting capacity of the immune system by stimulating selected immune cells. Cel-Sci is hopeful that this can be achieved using the company’s ligandepitope-antigen presentation system (‘LEAPS’) vaccine technology. One of the potential advantages of this technology is that it may alleviate the need for a carrier protein, thus simplifying the manufacturing process and reducing costs. The company hopes that this technology will be suitable for developing vaccines against viruses, bacteria and parasites, as well as those for use in cancer, autoimmune and allergic indications. Cel-Sci’s vicepresident of research Dr Daniel Zimmerman told Inpharma® that the company is ‘very excited’ about progress to date, particularly regarding the vaccines under development for the treatment of HIV infection.


Tuberculosis Malaria Major Histocompatibility Complex Class Keyhole Limpet Haemocyanin Vaccine Technology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1997

Authors and Affiliations

  • Gill Higgins

There are no affiliations available

Personalised recommendations